Baird analyst Eric Coldwell said they have long posited that Cardinal Health could well absorb the loss of OptumRx given strong underlying market fundamentals, recent performance, and solid BS/CF generation; and it was confirmed today by reiteration of long-term objectives. Baird believe that valuation remains attractive and theu maintain their Outperform rating and $134 price target on Cardinal Health shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH: